Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$4.49
$0.08(1.81%)
At close: 4:00 PM EDT
$4.49
$0.08(1.81%)
Day’s Range― - ―
52-Week Range$3.64 - $69.99
Previous CloseN/A
Volume8.49K
Average Volume (3M)557.82K
Market Cap
$45.24M
Enterprise Value$33.34
Total Cash (Recent Filing)$692.30K
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding6,416,540
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform T‑cell TechnologyA proprietary T‑cell platform is a durable strategic asset: it supports multiple indication programs, creates technology differentiation in immunotherapy, and can drive scalable R&D productivity over years. Platform breadth raises the probability that at least one program reaches late‑stage value creation.
Lower Debt LoadMaterial reduction in debt lessens near‑term refinancing pressure and interest burden, improving financial flexibility versus prior years. This creates a more durable runway for R&D activity and reduces the likelihood of urgent creditor-driven restructurings, though other capital risks remain.
Improving Loss TrendAn improvement in operating losses versus 2023 indicates progress toward controlling cash burn or lowering operating intensity. If sustained, this trend can lengthen the company’s financing runway and reflects operational adjustments that materially improve long‑term funding needs and program execution probability.
Bears Say
No RevenueAbsence of any commercial revenue means the business cannot self‑fund development and is fully reliant on external financing. This structural dependence elevates dilution and funding risk over the medium term and limits levers for durable margin improvement until a product is commercialized.
Sustained Cash BurnConsistent negative operating and free cash flow (~$12M TTM) creates an enduring need for financing to continue R&D and trials. Persistent cash burn constrains strategic optionality, increases dilution risk, and can delay or scale back programs if capital markets tighten over the next several quarters.
Negative Shareholders' EquitySustained negative equity signals solvency and capitalization weakness, limiting access to traditional financing and increasing cost of capital. It creates structural fragility: partners and creditors may demand stricter terms, and the company faces heightened risk if it must raise material funds or refinance obligations.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $3.64 and its highest was $69.99 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $45.24M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -$1.612 earnings per share for the quarter, beating the consensus estimate of -$2.64 by $1.028.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 6,416,540 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.612 in its last earnings report, beating expectations of -$2.64. Following the earnings report the stock price went up 6.966%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―
Ownership Overview
67.00% Insiders
0.72% Mutual Funds
<0.01% Other Institutional Investors
32.02% Public Companies and
Individual Investors